0R15 8520.0 0.0% 0R1E 8203.0 0.0% 0M69 21090.0 67.5139% 0R2V 226.02 9878.8079% 0QYR None None% 0QYP 412.97 -2.8306% 0RUK 2652.0 -9.2402% 0RYA 1554.0 -0.7029% 0RIH 174.55 -1.3563% 0RIH 165.15 -5.3853% 0R1O 198.5 9800.2494% 0R1O None None% 0QFP None None% 0M2Z 267.777 -0.1763% 0VSO 32.05 -9.9846% 0R1I None None% 0QZI 559.0 0.7207% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 165.7358 2.7149%
Last update at 2024-11-21T16:35:00Z
HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
Fri 30 Aug 24, 04:30 AMHUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
Wed 28 Aug 24, 04:24 PMHUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
Wed 21 Aug 24, 08:30 AMHUTCHMED Reports 2024 Interim Results and Provides Business Updates
Wed 31 Jul 24, 11:00 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -410.42200M | -215.74000M | -189.73400M | -141.10500M | -86.65500M |
| Minority interest | -0.44900M | -27.60700M | 34.83M | 24.89M | 23.26M |
| Net income | -410.13900M | -227.65800M | -194.56300M | -144.37900M | -74.80500M |
| Selling general administrative | 92.17M | 89.30M | 50.02M | 39.21M | 30.91M |
| Selling and marketing expenses | 43.93M | 37.83M | 11.33M | 13.72M | 17.74M |
| Gross profit | 115.31M | 97.89M | 39.46M | 44.74M | 70.17M |
| Reconciled depreciation | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M |
| Ebit | -409.77000M | -336.45800M | -188.94700M | -145.01900M | -69.83200M |
| Ebitda | -401.10600M | -329.26800M | -182.88600M | -135.13300M | -66.24200M |
| Depreciation and amortization | 8.66M | 7.19M | 6.06M | 9.89M | 3.59M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -409.77000M | -336.45800M | -188.94700M | -145.01900M | -92.64100M |
| Other operating expenses | 834.10M | 684.45M | 424.64M | 349.91M | 306.75M |
| Interest expense | 0.65M | 0.59M | 0.79M | 1.03M | 1.01M |
| Tax provision | -0.28300M | 11.92M | 4.83M | 3.27M | 3.96M |
| Interest income | 9.60M | 2.08M | 3.24M | 4.94M | 5.98M |
| Net interest income | 8.95M | 1.48M | 2.45M | 3.91M | 4.97M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.28300M | 11.92M | 4.83M | 3.27M | 3.96M |
| Total revenue | 426.41M | 356.13M | 227.98M | 204.89M | 214.11M |
| Total operating expenses | 523.00M | 426.21M | 236.12M | 189.76M | 162.81M |
| Cost of revenue | 311.10M | 258.23M | 188.52M | 160.15M | 143.94M |
| Total other income expense net | -0.65200M | 120.72M | -0.78700M | 3.91M | 5.99M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -360.38600M | -167.04100M | -115.51700M | -103.67900M | -71.28600M |
| Net income applicable to common shares | -360.83500M | -194.64800M | -125.73000M | -106.02400M | -74.80500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 1029.44M | 1372.66M | 724.12M | 465.12M | 532.12M |
| Intangible assets | - | 0.16M | 0.23M | 0.28M | 0.35M |
| Earning assets | - | - | - | - | - |
| Other current assets | 152.20M | 164.62M | 75.80M | 83.65M | 57.28M |
| Total liab | 392.57M | 333.15M | 205.17M | 152.22M | 119.86M |
| Total stockholder equity | 610.37M | 986.89M | 484.12M | 288.01M | 389.00M |
| Deferred long term liab | - | - | 1.17M | 0.18M | - |
| Other current liab | 282.79M | 17.19M | 0.37M | 0.45M | 59.30M |
| Common stock | 86.48M | 86.45M | 72.77M | 66.69M | 66.66M |
| Capital stock | 86.48M | 86.45M | 72.77M | 66.69M | 66.66M |
| Retained earnings | -971.48100M | -610.32800M | -415.59100M | -289.73400M | -183.00400M |
| Other liab | 15.37M | 14.33M | 13.27M | 8.67M | 7.07M |
| Good will | - | 3.38M | 3.31M | 3.11M | 3.19M |
| Other assets | 31.11M | 27.41M | 18.15M | 19.40M | 3.11M |
| Cash | 313.28M | 377.54M | 235.63M | 121.16M | 86.04M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 353.90M | 311.66M | 158.40M | 113.10M | 85.48M |
| Current deferred revenue | - | 226.38M | 123.63M | 85.48M | - |
| Net debt | -289.97800M | -343.47600M | -199.92000M | -88.07400M | -59.29700M |
| Short term debt | - | 26.91M | 2.79M | 3.22M | 214.91M |
| Short long term debt | 0.00000M | 26.91M | - | - | 0.00000M |
| Short long term debt total | 23.30M | 34.07M | 35.71M | 33.08M | 26.74M |
| Other stockholder equity | 1495.37M | 1510.77M | 826.93M | 511.06M | 525.17M |
| Property plant equipment | 84.67M | 53.15M | 32.19M | 26.37M | 16.62M |
| Total current assets | 839.89M | 1212.08M | 530.74M | 317.02M | 370.54M |
| Long term investments | - | - | - | 98.94M | 138.32M |
| Net tangible assets | 610.37M | 983.35M | 480.58M | 284.62M | 385.46M |
| Short term investments | 317.72M | 634.16M | 199.55M | 96.01M | 214.91M |
| Net receivables | 97.99M | 147.73M | 64.44M | 77.35M | 51.23M |
| Long term debt | 18.10M | 0.00000M | 26.86M | 26.82M | 26.74M |
| Inventory | 56.69M | 35.76M | 19.77M | 16.21M | 12.31M |
| Accounts payable | 71.11M | 41.18M | 31.61M | 23.96M | 25.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -26.28100M | -23.35200M | -19.82600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 72.77M | 66.69M | 66.66M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 333.46M | 639.00M | 203.06M | 113.48M | 216.27M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 189.56M | 160.59M | 193.38M | 148.10M | 161.58M |
| Capital lease obligations | 5.20M | 7.16M | 8.85M | 6.26M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 296.59M | -275.49400M | -103.53500M | 118.90M | 50.12M |
| Change to liabilities | 30.32M | 20.64M | 7.49M | -2.37300M | 1.02M |
| Total cashflows from investing activities | 296.59M | -306.32000M | -125.44100M | 119.03M | 43.75M |
| Net borrowings | -9.17000M | -0.57900M | -0.57900M | -0.11600M | -4.62700M |
| Total cash from financing activities | -82.76300M | 650.03M | 296.43M | -1.49300M | -8.23100M |
| Change to operating activities | 64.04M | 63.46M | 30.10M | 22.96M | 7.18M |
| Net income | -360.38600M | -167.04100M | -115.51700M | -103.67900M | -71.28600M |
| Change in cash | -64.26400M | 141.91M | 114.47M | 35.12M | 0.77M |
| Begin period cash flow | 377.54M | 235.63M | 121.16M | 86.04M | 85.27M |
| End period cash flow | 313.28M | 377.54M | 235.63M | 121.16M | 86.04M |
| Total cash from operating activities | -268.59900M | -204.22300M | -62.06600M | -80.91200M | -32.84700M |
| Issuance of capital stock | 0.17M | 717.32M | 318.93M | 0.25M | 3.87M |
| Depreciation | 8.66M | 7.19M | 6.06M | 4.94M | 3.59M |
| Other cashflows from investing activities | - | -15.00000M | -105.86100M | 127.59M | 50.12M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -21.21300M | -16.00200M | -3.62300M | -4.21500M | -0.55700M |
| Change to account receivables | -14.45100M | -35.63400M | -4.69300M | -0.27100M | -0.48600M |
| Sale purchase of stock | -48.08400M | -27.30900M | -12.90400M | -0.34600M | -5.45100M |
| Other cashflows from financing activities | -7.93000M | -39.98200M | -9.59600M | 25.52M | 23.35M |
| Change to netincome | 24.85M | -49.26700M | 28.29M | 3.87M | 31.13M |
| Capital expenditures | 36.66M | 16.76M | 19.58M | 8.56M | 6.36M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 58.70M | 32.46M | 29.27M | 16.11M | 6.96M |
| Stock based compensation | 30.59M | 41.99M | 19.64M | 11.59M | 10.13M |
| Other non cash items | -6.16700M | -3.68300M | -2.07700M | 0.39M | 17.76M |
| Free cash flow | -305.26300M | -220.97900M | -81.64600M | -89.47700M | -39.21100M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HCM HUTCHMED China Ltd |
-3.0 1.06% | 281.00 | - | - | 3.22 | 3.97 | 2.39 | -19.4252 |
| HLN Haleon PLC |
3.80 1.03% | 372.40 | 24.73 | 16.86 | 2.63 | 1.81 | 3.17 | 16.57 |
| HIK Hikma Pharmaceuticals PLC |
27.00 1.46% | 1872.00 | 33.45 | 11.14 | 1.45 | 2.32 | 1.76 | 8.98 |
| INDV Indivior PLC |
10.50 1.27% | 837.00 | - | - | 1.60 | 48.69 | 1.17 | -4.7616 |
| BXP Beximco Pharmaceuticals Limited |
- -% | 33.50 | 5.86 | 4.52 | 0.01 | 0.59 | 0.01 | 0.06 |
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
Cheung Kong Center, Central, Hong Kong
| Name | Title | Year Born |
|---|---|---|
| Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA | Exec. Chairman | 1952 |
| Dr. Weiguo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Exec. Director | 1957 |
| Mr. Chig Fung Cheng BEc, CA | CFO & Exec. Director | 1967 |
| Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito | Company Sec. & Non-Exec. Director | 1952 |
| Dr. Karen Jane Atkin | Exec. VP & COO | 1966 |
| Mr. Kin Hung Lee M.B.A. | Sr. VP of Corp. Fin. & Devel. | 1977 |
| Mr. Charles George Rupert Nixon | Group Gen. Counsel | 1970 |
| Ms. Selina Zhang | Sr. VP of Global HR | NA |
| Dr. Qingmei Wang Ph.D. | Sr. VP of Bus. Devel. & Strategic Alliances | 1963 |
| Mr. Hong Chen | Sr. VP & Chief Commercial Officer- China | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...